Adcendo
Developer of antibody-drug conjugates (ADCs) for cancer treatment.
6
Funding Rounds
$61.8m
Money raised
Overview
Developer of antibody-drug conjugates (ADCs) for cancer treatment.
- Website:
- Business model: B2B
- Headquarters: Copenhagen
- Social accounts: linkedin
| Name | Phone | Social networks | |
|---|---|---|---|
| He**** St*** |
|
- | - |
| Ch********* Ni***** |
|
- | |
| La** H. En******* |
|
- | - |
| Ni*** Be****** |
|
- | - |
Funding
Funding series
Funding Series Analysis
The company Adcendo has raised a total of $311.2m in funding over 6 rounds.
Key Insights:
- Adcendo Series B Round, November 2024: $135m
- Adcendo May 2024 Series A Funding Round: $17m
- Adcendo April 2023 Series A Funding Round: $34m
- ADCendo Series A round, April 2021: $61.8m
- Adcendo April 2021 Series A Funding Round: $62m
- Adcendo August 2019 Debt Funding Round: $1.4m
Adcendo Series B Round, November 2024
$135m
Adcendo May 2024 Series A Funding Round
$17m
Adcendo April 2023 Series A Funding Round
$34m
ADCendo Series A round, April 2021
$61.8m
Adcendo April 2021 Series A Funding Round
$62m
Adcendo August 2019 Debt Funding Round
$1.4m
Industries
Adcendo is active in the following industries: